Does Netupitant And Palonosetron Interact with Ifosfamide?
CDI records a moderate classification for Netupitant And Palonosetron and Ifosfamide. The stored summary is: Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised. The mechanism involves cyp3a4 inhibition by netupitant. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
Evidence status
A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.
Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.
- Stored CDI classification
- Moderate
- Netupitant And Palonosetron Class
- Serotonin-3 Receptor Antagonist
- Ifosfamide Class
- Alkylating Drug
- Management
- Confirm exact products with your pharmacist
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4 inhibition by netupitant
What To Tell Your Doctor or Pharmacist
If you are taking Netupitant And Palonosetron and your doctor is considering prescribing Ifosfamide (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider